ArticlePloS one2020
A novel drug repurposing approach for non-small cell lung cancer using deep learning.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 56 citations in OpenAlex.
- Metronomic Chemotherapy in Ovarian Cancer: Current Scenario and AI-Integrated Future Strategies.Cancer reports (Hoboken, N.J.) · 2026Review
- Emerging Anti-Cancer and Repurposed Therapies for Overcoming Multidrug Resistance in Lung Cancer.Medical oncology (Northwood, London, England) · 2025Review
- Discovery of drug candidate to inhibit bronchogenic carcinoma genes biomarkers based on drug repurposing.Discover oncology · 2025Article
- Advances in Computational Drug Repurposing, Driver Genes, and Therapeutics in Lung Adenocarcinoma.Biomolecules · 2025Review
- Are metformin-based combination approaches beneficial for non-small cell lung cancer: evidence from experimental and clinical studies.Military Medical Research · 2025Review
- AI-driven drug discovery and repurposing using multi-omics for myocardial infarction and heart failure.Exploration of medicine · 2025Article
- Review
- In Silico Identification of a Potential TNF-Alpha Binder Using a Structural Similarity: A Potential Drug Repurposing Approach to the Management of Alzheimer's Disease.BioMed research international · 2024Article
- Optimized models and deep learning methods for drug response prediction in cancer treatments: a review.PeerJ. Computer science · 2024Article
- Trends in the approval of cancer therapies by the FDA in the twenty-first century.Nature reviews. Drug discovery · 2023Review
- Integration of artificial intelligence in lung cancer: Rise of the machine.Cell reports. Medicine · 2023Review
- Omics Data and Data Representations for Deep Learning-Based Predictive Modeling.International journal of molecular sciences · 2022Review
- Lung adenocarcinoma-related target gene prediction and drug repositioning.Frontiers in pharmacology · 2022Article
- Recent advances in drug repurposing using machine learning.Current opinion in chemical biology · 2021Review
- Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents.Molecular diversity · 2021Article
- Artificial intelligence to deep learning: machine intelligence approach for drug discovery.Molecular diversity · 2021Review
- Artificial Intelligence in Cancer Research and Precision Medicine.Cancer discovery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug repurposing is an attractive and pragmatic way offering reduced risks and development time in the complicated process of drug discovery. In the past, drug repurposing has been largely accidental and serendipitous. The most successful examples so far have not involved a systematic approach. Nowadays, remarkable advances in drugs, diseases and bioinformatic knowledge are offering great opportunities for designing novel drug repurposing approach through comprehensive understanding of drug information. In this study, we introduced a novel drug repurposing approach based on transcriptomic data and chemical structures using deep learning. One strong candidate for repurposing has been identified. Pimozide is an anti-dyskinesia agent that is used for the suppression of motor and phonic tics in patients with Tourette's Disorder. However, our pipeline proposed it as a strong candidate for treating non-small cell lung cancer. The cytotoxicity of pimozide against A549 cell lines has been validated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.